α1アンチトリプシン欠損症における健康な患者の保護要因を解明(Alpha-1 antitrypsin deficiency: What protects the one – and not the other?)

ad

2025-04-16 マックス・プランク研究所

マックス・プランク生化学研究所の研究チームは、遺伝性疾患であるα1-アンチトリプシン欠損症(AATD)において、同じ遺伝子変異を持つにもかかわらず、重度の肝線維症を発症する患者と健康を維持する患者が存在する理由を解明した。AIと質量分析を融合した「Deep Visual Proteomics」技術を用い、肝組織におけるタンパク質パターンの違いを解析。早期段階から肝細胞が活性化する自然修復機構の存在が、発症予防に寄与している可能性が示唆された。この知見は、将来的に肝線維症の早期警告システム開発に応用されると期待される。

<関連情報>

ディープ・ビジュアル・プロテオミクスが遺伝性肝疾患におけるタンパク質毒性をマッピング Deep Visual Proteomics maps proteotoxicity in a genetic liver disease

Florian A. Rosenberger,Sophia C. Mädler,Katrine Holtz Thorhauge,Sophia Steigerwald,Malin Fromme,Mikhail Lebedev,Caroline A. M. Weiss,Marc Oeller,Maria Wahle,Andreas Metousis,Maximilian Zwiebel,Niklas A. Schmacke,Sönke Detlefsen,Peter Boor,Ondřej Fabián,Soňa Fraňková,Aleksander Krag,Pavel Strnad & Matthias Mann
Nature  Published:16 April 2025
DOI:https://doi.org/10.1038/s41586-025-08885-4

α1アンチトリプシン欠損症における健康な患者の保護要因を解明(Alpha-1 antitrypsin deficiency: What protects the one – and not the other?)

Abstract

Protein misfolding diseases, including α1-antitrypsin deficiency (AATD), pose substantial health challenges, with their cellular progression still poorly understood1,2,3. We use spatial proteomics by mass spectrometry and machine learning to map AATD in human liver tissue. Combining Deep Visual Proteomics (DVP) with single-cell analysis4,5, we probe intact patient biopsies to resolve molecular events during hepatocyte stress in pseudotime across fibrosis stages. We achieve proteome depth of up to 4,300 proteins from one-third of a single cell in formalin-fixed, paraffin-embedded tissue. This dataset reveals a potentially clinically actionable peroxisomal upregulation that precedes the canonical unfolded protein response. Our single-cell proteomics data show α1-antitrypsin accumulation is largely cell-intrinsic, with minimal stress propagation between hepatocytes. We integrated proteomic data with artificial intelligence-guided image-based phenotyping across several disease stages, revealing a late-stage hepatocyte phenotype characterized by globular protein aggregates and distinct proteomic signatures, notably including elevated TNFSF10 (also known as TRAIL) amounts. This phenotype may represent a critical disease progression stage. Our study offers new insights into AATD pathogenesis and introduces a powerful methodology for high-resolution, in situ proteomic analysis of complex tissues. This approach holds potential to unravel molecular mechanisms in various protein misfolding disorders, setting a new standard for understanding disease progression at the single-cell level in human tissue.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました